Spero Therapeutics (SPRO) Net Cash Flow (2016 - 2026)
Spero Therapeutics' (SPRO) quarterly Net Cash Flow came in at $15.9 million in Q1 2026, up 496.4% YoY from $2.7 million in Q1 2025, and up 289.97% on a QoQ basis from -$8.4 million in Q4 2025.
Spero Therapeutics (SPRO) Net Cash Flow (2016 - 2026) Analysis & Trends
Spero Therapeutics (SPRO) has 11 years of Net Cash Flow data on file, last reported at $15.9 million in Q1 2026.
- Quarterly Net Cash Flow rose 496.4% year-over-year to $15.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.2 million (up 121.69% YoY) and the FY2025 annual result came in at -$12.6 million, up 46.15% from the prior year.
- Net Cash Flow improved to $15.9 million in Q1 2026, from -$8.4 million in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of $58.7 million in Q4 2022 to a low of -$40.5 million in Q1 2022.
- A 5-year average of -$3.3 million and a median of -$8.4 million in 2025 frame the typical range for Net Cash Flow.
- The widest YoY moves for Net Cash Flow: up 21431.27% in 2022, down 395.57% in 2022.
- Tracing SPRO's Net Cash Flow over 5 years: stood at $58.7 million in 2022, then sank by 129.82% to -$17.5 million in 2023, then sank by 33.78% to -$23.4 million in 2024, then surged by 64.31% to -$8.4 million in 2025, then soared by 289.97% to $15.9 million in 2026.
- The last three Net Cash Flow figures came in at $15.9 million (Q1 2026), -$8.4 million (Q4 2025), and $17.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -496,000.00 |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -37.14 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 225.59 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -2.83 Bn |
| 10 | Spero Therapeutics | 70.14 Mn | 19.37 Mn | - | -5.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -5.36 Mn |
| Jun 30, 2026 | -5.36 Mn |
| Mar 31, 2026 | 15.86 Mn |
| Mar 31, 2026 | 15.86 Mn |
| Dec 31, 2025 | -8.35 Mn |
| Dec 31, 2025 | -8.35 Mn |
| Sep 30, 2025 | 17.42 Mn |
| Sep 30, 2025 | 17.42 Mn |
| Jun 30, 2025 | -17.69 Mn |
| Jun 30, 2025 | -17.69 Mn |
| Mar 31, 2025 | -4.00 Mn |
| Mar 31, 2025 | -4.00 Mn |
| Dec 31, 2024 | -23.40 Mn |
| Dec 31, 2024 | -23.40 Mn |
| Sep 30, 2024 | 12.76 Mn |
| Sep 30, 2024 | 12.76 Mn |
| Jun 30, 2024 | -18.74 Mn |
| Jun 30, 2024 | -18.74 Mn |
| Mar 31, 2024 | 5.94 Mn |
| Mar 31, 2024 | 5.94 Mn |